Compare Amgen, Inc. (AMGN) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Amgen, Inc. trades at $358.69 (market cap $196.12B), while Direxion Daily Semiconductor Bear 3X Shares trades at $4.58. The key difference: Amgen, Inc. pays a 2.77% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none, and Amgen, Inc. is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals.
| AMGN | SOXS | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $160.60 |
52-Week Low | $271.18 | $3.25 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SOXS, the Direxion Daily Semiconductor Bear 3X Shares ETF, trades at $4.08 with minimal daily movement (+0.25%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, while oscillators remain neutral. The ETF is preparing for a 1:10 stock split effective July 15, 2026, and declared a $0.04 dividend for H1-2026. Recent news highlights the challenging environment for bearish semiconductor bets amid an ongoing AI-driven chip rally that has pressured inverse ETFs.
The outlook for SOXS remains highly speculative and risky, suitable only for sophisticated traders seeking short-term inverse exposure to semiconductors. The primary opportunity lies in potential semiconductor sector volatility or correction, while significant risks include continued AI-driven bullish momentum and the structural decay inherent in leveraged inverse ETFs during sustained market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
